(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 August 2011 (04.08.2011)

PCT

(10) International Publication Number
WO 2011/094259 A3

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2011/022507

(22) International Filing Date:
26 January 2011 (26.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/299,010 28 January 2010 (28.01.2010) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenfor, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIRBY, Ian** [GB/GB]; Gunnels Wood, Stevenage, Hertfordshire SG1 2NY (GB). **TAYLOR, Alexander, H.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **WEBB, Thomas, Matthew** [GB/GB]; Gunnels Wood, Stevenage, Hertfordshire SG1 2NY (GB). **XUE, Yu** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US).

(74) Agents: **FEDON, Jason** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swendeland Road, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
29 September 2011

WO 2011/094259 A3

(54) Title: CD127 BINDING PROTEINS

(57) Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.